

Applicant : Signe M. Christenson et al.
Serial No. : 10/535,472
Filed : December 19, 2005
Page : 2 of 13

Attorney's Docket No.: 22460-0003US1 / 1015US2;
Inspicos 16215US00

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-42. (Cancelled)

43. (Currently amended) An oligonucleotide consisting of between 10-30 nucleotide units, which contains three adjacently located nucleotide sequences, A, B and C, in the following order (5' to 3'):

A-B-C or C-B-A,

in which

A consists of between 2 and 8 [[5]] locked nucleotide units, wherein ~~between 1 and 5 of the nucleotide units in A are locked nucleotide units;~~

B consists of no more than ~~between 5 and 10~~ nucleotide units, wherein B comprises ~~nucleotide units selected from the group consisting of only 3, 4, or 5 contiguous 2'-deoxy-erythro-pentofuranosyl nucleotide units, ribo-pentofuranosyl and alpha-L-oxy LNA nucleotide units, wherein B and~~ comprises at least one alpha-L-oxy LNA nucleotide unit; and

C consists of between 2 and 8 [[5]] locked nucleotides units ~~wherein between 1 and 5 of the nucleotide units in C are locked nucleotide units, wherein one or both of A and C comprise at least two consecutive locked nucleotide units.~~

44. (Previously presented) The oligonucleotide according to claim 43, in which B represents a sequence of nucleotide units that makes the oligonucleotide able to recruit RNase H when the oligonucleotide is hybridized to a target RNA molecule.

45. (Previously presented) The oligonucleotide according to claim 44, in which B consists of 2'-deoxy-erythro-pentofuranosyl nucleotide units and alpha-L-oxy LNA nucleotide units.

46. (Previously presented) The oligonucleotide a according to claim 45, wherein the locked nucleotide units in A and C are selected from the group consisting of oxy-LNA, thio-LNA and amino-LNA nucleotide units, wherein the LNA nucleotide units are in either the alpha or beta configuration.

47. (Previously presented) The oligonucleotide according to claim 45, wherein the locked nucleotide units in A and C are beta-D-oxy-LNA nucleotide units.

48-53. (Canceled)

54. (Previously presented) The oligonucleotide according to claim 45, wherein A consists of 2, 3, 4 or 5 LNA nucleotide units.

55. (Previously presented) The oligonucleotide according to claim 45, wherein C consists of 2, 3, 4 or 5 LNA nucleotide units.

56. (Previously presented) The oligonucleotide according to claim 54, wherein C consists of 2, 3, 4 or 5 LNA nucleotide units.

57. (Previously presented) The oligonucleotide according to claim 45, wherein the oligonucleotide consists of 10-20 nucleotide units.

58. (Previously presented) The oligonucleotide according to claim 45, wherein the oligonucleotide consists of 12-18 nucleotide units.

59. (Previously presented) The oligonucleotide according to claim 45, wherein the oligonucleotide consists of 13, 14, 15, 16 or 17 nucleotide units.

60. (Previously presented) The oligonucleotide according to claim 45, wherein the oligonucleotide consists of 16 nucleotide units.

61. (Cancelled)

62. (Previously presented) The oligonucleotide according to claim 45, wherein B consists of 5, 6, 7 or 8 nucleotide units.

63-64. (Cancelled)

65. (Previously presented) The oligonucleotide according to claim 45, in which the linkages between the nucleotide units in the oligonucleotide comprise at least one linkage which is not a -O-P(O)₂-O- linkage

66. (Previously presented) The oligonucleotide according to claim 45, in which the linkages between the nucleotide units in B in the oligonucleotide comprises at least one phosphothioate linkage

67. (Previously presented) The oligonucleotide according to claim 45, wherein the linkages between the nucleotide units are phosphorothioate internucleoside linkages.

68. (Cancelled)

69. (Currently amended) A composition comprising an oligonucleotide according to any of claims 43-47, 54-60, 62 and [[65-68]] 65-67.

70. (Currently amended) A pharmaceutical composition comprising an oligonucleotide according to any of claims 43-47, 54-60, 62 and [[65-68]] 65-67 and a pharmaceutically acceptable carrier.

71. (Cancelled)

72. (Previously presented) The pharmaceutical composition according to claim 70, which further comprises a second antisense compound, a chemotherapeutic compound, an antiinflammatory compound and/or an antiviral compound.